StockData
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX) stock

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)

Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%

Nurix Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Nurix Therapeutics's price to sales ratio was 2.5× on Nov 11, 2026, against 16.2× a year earlier. Over the last 5 years it ranged from 2.5× to 72.7×, with a median of 15.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.5×−14.9
2025Dec 31, 202517.4×−5.0
2024Dec 31, 202422.4×+15.1
2023Dec 29, 20237.3×−5.9
2022Dec 30, 202213.2×−31.2
2021Dec 31, 202144.4×−53.9
2020Dec 31, 202098.3×–

More Nurix Therapeutics figures

See a number that looks wrong?